Argenica Therapeutics (ASX:AGN) has released initial preclinical data on the ability of its ARG007 to inhibit human recombinant Amyloid-Beta (Abeta) aggregation in a preclinical model of Alzheimer’s disease.
Abeta aggregation is thought to be one of the main causes of Alzheimer’s Disease.
The aim of the preclinical study was to determine the effects of ARG-007 in comparison to controls in inhibiting human recombinant Abeta aggregation using the cell-free Abeta aggregation assay.
The company said the results show that ARG-007 has a positive effect in inhibiting Abeta aggregation at the 10-hour and 16-hour post-administration time points, compared to the vehicle controls.
Argenica managing director Dr Liz Dallimore said, “This is extremely encouraging data showing a potential new indication for ARG-007. It is well recognised that Abeta aggregation in the brain plays a key role in initiating Alzheimer’s Disease, and therefore a safe therapeutic drug that can reduce Abeta aggregation is a huge opportunity. We look forward to continuing to progress this exciting opportunity into further animal studies.”